3 Global Pharma Major, Chronic Care Brands and Nutrition Ingredients Stocks With a Strong Future Roadmap: Lupin, Eris Lifesciences and Sudeep Pharma

Pharma portfolio stocks bring together companies that earn from many parts of the health chain, from finished medicines to ingredients. Lupin, Eris Lifesciences and Sudeep Pharma cover a global pharmaceutical major, a chronic care branded formulations company and a maker of excipients and nutritional ingredients.

This list covers three pharma portfolio stocks with complete current figures: Lupin, Eris Lifesciences and Sudeep Pharma. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pharma Portfolio Stocks?

Pharma portfolio stocks are listed companies with a mix of branded formulations, generics, ingredients and nutrition products. A varied portfolio spreads their earnings across therapies and customers.

Pharma Portfolio Stocks at a Glance

On valuation, Lupin and Eris Lifesciences trade at a P/E below the industry P/E, while Sudeep Pharma trades above it, which reflects the growth the market already expects. Readers comparing pharma portfolio stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Pharma Portfolio Stocks Have a Strong Roadmap in India?

Pharma portfolio stocks have a strong roadmap in India because demand for medicines, supplements and quality ingredients is rising, and varied product lines help companies grow through the cycle.

• Chronic therapies. Heart, diabetes and gut conditions create repeat prescriptions.
• Specialty launches. New products in respiratory and complex generics earn better pricing.
• Ingredient quality. Certified excipients and nutrition inputs find global buyers.

Why Lupin Features Among These Pharma Portfolio Stocks

Among the pharma portfolio stocks on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.

Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%.

In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.

Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.

Why Eris Lifesciences Features Among These Pharma Portfolio Stocks

Among the global pharma shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.

In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%.

Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.

Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.

Why Sudeep Pharma Features Among These Pharma Portfolio Stocks

Among the three companies on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.

The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1.

Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore.

Roadmap: Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.

What to watch: Check capacity expansion progress and export revenue growth.

Lupin vs Eris Lifesciences vs Sudeep Pharma on Key Financials

The table below sets the three pharma portfolio stocks side by side on revenue, profit and margin, using reported figures.

Lupin posts the highest return on equity in this group at 23.8%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with pharma portfolio stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Pharma Portfolio Stocks

Every theme carries risks that deserve a check before any decision. For these pharma portfolio stocks, the main points are: Long-term global pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Launch timing. Revenue from new products depends on approvals and uptake.
• Pricing rules. Government price limits can influence domestic margins.
• Input costs. Raw material prices can influence margins.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter pharma portfolio stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Pharma Portfolio Stocks

Pharma portfolio stocks suit investors who prefer a spread of therapies and products. Lupin, Eris Lifesciences and Sudeep Pharma each balance steady demand with a clear plan for growth. Based on the 20 October 2026 close, Lupin trades at Rs 1,939.2, Eris Lifesciences at Rs 1,120.4 and Sudeep Pharma at Rs 1,003.3.

Download the Univest iOS App or Univest Android App to track pharma portfolio stocks, set price alerts and get research-backed stock ideas.

What are pharma portfolio stocks?

Ans. Pharma portfolio stocks are listed companies with a mix of branded formulations, generics, ingredients and nutrition products. A varied portfolio spreads their earnings across therapies and customers. This list looks at three of them, Lupin, Eris Lifesciences and Sudeep Pharma, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.

Which pharma portfolio stocks are covered in this list?

Ans. This list covers Lupin, Eris Lifesciences and Sudeep Pharma. Based on the 20 October 2026 close, Lupin traded at Rs 1,939.2, Eris Lifesciences at Rs 1,120.4 and Sudeep Pharma at Rs 1,003.3. Their return on equity ranges from 15.9% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.0% to 22.9%.

Why do pharma portfolio stocks have a strong future roadmap in India?

Ans. Pharma portfolio stocks have a strong roadmap in India because demand for medicines, supplements and quality ingredients is rising, and varied product lines help companies grow through the cycle. The main drivers are as follows. Chronic therapies. Heart, diabetes and gut conditions create repeat prescriptions. Specialty launches. New products in respiratory and complex generics earn better pricing. Ingredient quality. Certified excipients and nutrition inputs find global buyers. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Lupin performed financially?

Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

How has Eris Lifesciences performed financially?

Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

How has Sudeep Pharma performed financially?

Ans. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.

What risks should investors check before buying pharma portfolio stocks?

Ans. Investors should check a few risks before buying pharma portfolio stocks. Launch timing. Revenue from new products depends on approvals and uptake. Pricing rules. Government price limits can influence domestic margins. Input costs. Raw material prices can influence margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of pharma portfolio stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.